• Explore /
  • Poster
  • / Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).

Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).

Abstract Poster

Authors

null

Shubham Pant

University of Texas MD Anderson Cancer Center, Houston, TX

Shubham Pant , Alexander I. Spira , Byoung Chul Cho , Sanjay Goel , Christopher J. Hoimes , Ajjai Shivaram Alva , Rama Balaraman , Todd Michael Bauer , Philip A. Lowry , Ryan C. Ramaekers , Robert D. Siegel , Theresa Louise Werner , Nizar M. Tannir , Demiana Faltaos , Diane Potvin , Saskia T.C. Neuteboom , James Christensen , Richard C. Chao , Christos Kyriakopoulos

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT02219711

Citation

J Clin Oncol 36, 2018 (suppl; abstr 4568)

DOI

10.1200/JCO.2018.36.15_suppl.4568

Abstract #

4568

Poster Bd #

394

Abstract Disclosures

Similar Posters

First Author: Pavlos Msaouel

First Author: Jose A. Karam

First Author: Todd Michael Bauer

First Author: Tomoko Hirohashi